EMAIL THIS PAGE TO A FRIEND

Journal of cardiology

Role of epicardial adipose tissue in coronary artery disease in non-obese patients.


PMID 24230463

Abstract

Epicardial adipose tissue (EAT) surrounding the heart may contribute to the development of coronary artery disease (CAD) through its local secretion of adipocytokines. Although the quantity of EAT is associated with obesity and metabolic syndrome, the role of EAT in the development of CAD in non-obese patients remains to be determined. This study included 41 patients with CAD who underwent coronary artery bypass graft surgery and 28 patients without CAD who underwent other cardiac surgery. EAT volume was measured by 64-slice multi-detector computed tomography before the surgery. We obtained pericardial fluid and epicardial and subcutaneous adipose tissue samples at the surgery. We investigated the relationship between EAT volume and adiponectin levels in pericardial fluid and incident CAD in patients with and without obesity (body mass index>25 kg/m(2)). There was no significant difference in EAT volume between obese patients with and without CAD (55.5 ± 40.2 mL vs. 40.1 ± 19.7 mL, p=0.323). However, EAT volume was significantly greater in non-obese patients with CAD compared to those without CAD (35.0 ± 18.8 mL vs. 15.7 ± 11.0 mL, p<0.001). Adiponectin concentrations in pericardial fluid were significantly lower in non-obese patients with CAD compared to those without CAD (2.7 ± 2.0 μg/mL vs. 4.3 ± 3.7 μg/mL, p=0.049), whereas the adiponectin levels were decreased in obese patients regardless of the presence of CAD. Non-obese patients with CAD had significantly larger size adipocytes in EAT but not subcutaneous adipose tissue compared to those without CAD. Multiple logistic regression analysis showed that increased EAT volume was independently associated with incident CAD in non-obese patients. Increased EAT may play a crucial role in development of CAD through impairment of adiponectin secretion in non-obese patients.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

D5905
3,3′-Diaminobenzidine tetrahydrochloride, tablet, 10 mg substrate per tablet
C12H14N4 · 4HCl
AV32799
Anti-ACDC antibody produced in rabbit, IgG fraction of antiserum
PRS3551
Anti-Adiponectin (ab1) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
PRS3553
Anti-Adiponectin (ab2) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
A6354
Anti-Adiponectin antibody produced in rabbit, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution
SAB1411845 ANTI-ADIPOQ antibody produced in mouse, clone 4E12, purified immunoglobulin, buffered aqueous solution
SAB1411846 ANTI-ADIPOQ antibody produced in mouse, clone 3H2, purified immunoglobulin, buffered aqueous solution
SAB1411847 ANTI-ADIPOQ antibody produced in mouse, clone 2G12, purified immunoglobulin, buffered aqueous solution
SAB1411848 ANTI-ADIPOQ antibody produced in mouse, clone 4F5, purified immunoglobulin, buffered aqueous solution
SAB1411849 ANTI-ADIPOQ antibody produced in mouse, clone 2H6, purified immunoglobulin, buffered aqueous solution
SAB1411850 ANTI-ADIPOQ antibody produced in mouse, clone 2A11, purified immunoglobulin, buffered aqueous solution
SAB1411851 ANTI-ADIPOQ antibody produced in mouse, clone 4H2, purified immunoglobulin, buffered aqueous solution
SAB1411852 ANTI-ADIPOQ antibody produced in mouse, clone 1F3, purified immunoglobulin, buffered aqueous solution
SAB1411853 ANTI-ADIPOQ antibody produced in mouse, clone 4G9, purified immunoglobulin, buffered aqueous solution
SAB1411854 ANTI-ADIPOQ antibody produced in mouse, clone 2G9, purified immunoglobulin, buffered aqueous solution
1344702 Iopamidol, United States Pharmacopeia (USP) Reference Standard
C17H22I3N3O8
I0329000 Iopamidol, European Pharmacopoeia (EP) Reference Standard
C17H22I3N3O8